Overexpression of suppressor of IKBKE 1 is associated with vincristine resistance in colon cancer cells

Chun-hua, Zhao; Xu, Zhongjie; Guo, Qing; Li, Yun‐Xiao; Gao, Xiangzheng; Peng, Yi‐You

doi:10.3892/br.2016.759

Cited by 3 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Colon cancer is the third most common malignancy both in terms of estimated new cases and estimated deaths in 2016 [ 32 ]. Although enormous efforts have been made in early diagnosis and therapy, many patients have died of drug-resistant recurrence and progress in improving overall survival has been relatively slow [ 33 ]. The development of novel agents offers an alternative strategy against drug-resistance in colon cancer.…”

Section: Discussionmentioning

confidence: 99%

Shikonin induces ROS-based mitochondria-mediated apoptosis in colon cancer

et al. 2017

View full text Add to dashboard Cite

Colon cancer is the third most common malignancy worldwide, and chemotherapy is a widely used strategy in clinical therapy. Chemotherapy-resistant of colon cancer is the main cause of recurrence and progression. Novel drugs with efficacy and safety in treating colon cancer are urgently needed. Shikonin, a naphthoquinone derived from the roots of the herbal plant Lithospermum erythrorhizon, has been determined to be a potent anti-tumor agent. The aim of the present study was to detect the underlying anti-tumor mechanism of shikonin in colon cancer. We found that shikonin suppressed the growth of colon cancer cells in a dose-dependent manner in vitro and in vivo. Shikonin induced mitochondria-mediated apoptosis, which was regulated by Bcl-2 family proteins. Shikonin increased the generation of intracellular ROS, which played an upstream role in shikonin-induced apoptosis. Our data indicated that generation of ROS, down-regulated expression of Bcl-2 and Bcl-xL, depolarization of the mitochondrial membrane potential and activation of the caspase cascade were components of the programmed event of shikonin-induced apoptosis in colon cancer cells. In addition, shikonin presented minimal toxicity to non-neoplastic colon cells and no liver injury in xenograft models, showing safety in the control of colon cancer cell growth in vitro and in vivo. Taken together, our findings suggest that shikonin might serve as a potential novel therapeutic drug in the treatment of human colon cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Shikonin induces ROS-based mitochondria-mediated apoptosis in colon cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…However, many patients have died from chemotherapy resistance, disease progression, and recurrence. Progress in improving overall survival has been relatively slow[ 20 ]. Hence, searching for effective chemotherapy drugs and overcoming drug resistance is a looming problem.…”

Section: Discussionmentioning

confidence: 99%

Tetramethylpyrazine inhibits proliferation of colon cancer cells in vitro

Hou

et al. 2021

WJCC

View full text Add to dashboard Cite

BACKGROUND Colon cancer is one of the most common malignancies worldwide, and chemotherapy is a widely used strategy in colon cancer clinical therapy. However, chemotherapy resistance is a major cause of disease recurrence and progression in colon cancer, and thus novel drugs for treatment are urgently needed. Tetramethylpyrazine (TMP), a component of the traditional Chinese medicine Chuanxiong Hort, has been proven to exhibit a beneficial effect in tumors. AIM To investigate the potential anticancer activity of TMP in colon cancer and its underlying mechanisms. METHODS Colon cancer cells were incubated with different concentrations of TMP. Cell viability was evaluated by crystal violet staining assay and cell counting kit-8 assay, and cell apoptosis and cell cycle were assessed by flow cytometry. RESULTS TMP significantly inhibited the proliferation of colon cancer cells in a dose- and time-dependent manner. In addition, flow cytometry revealed that TMP induced cell cycle arrest at the G0/G1 phase. TMP treatment caused early stage apoptosis in SW480 cells, whereas it caused late stage apoptosis in HCT116 cells. CONCLUSION Our studies demonstrated that TMP inhibits the proliferation of colon cancer cells in a dose- and time-dependent manner by inducing apoptosis and arresting the cell cycle at the G0/G1 phase. Our findings suggest that TMP might serve as a potential novel therapeutic drug in the treatment of human colon cancer.

show abstract

Advances in IKBKE as a potential target for cancer therapy

2019

View full text Add to dashboard Cite

IKBKE (inhibitor of nuclear factor kappa‐B kinase subunit epsilon), a member of the nonclassical IKK family, plays an important role in the regulation of inflammatory reactions, activation and proliferation of immune cells, and metabolic diseases. Recent studies have demonstrated that IKBKE plays a crucial regulatory role in malignant tumor development. In recent years, IKBKE, an important oncoprotein in several kinds of tumors, has been widely found to regulate a variety of cytokines and signaling pathways. IKBKE promotes the growth, proliferation, invasion, and drug resistance of various cancers. This paper makes a detailed review that focuses on the recent discoveries of IKBKE in the malignant tumors, and puts forward that IKBKE is becoming an important therapeutic target for clinical treatment, which has been more and more realized.

show abstract

Overexpression of suppressor of IKBKE 1 is associated with vincristine resistance in colon cancer cells

Cited by 3 publications

References 23 publications

Shikonin induces ROS-based mitochondria-mediated apoptosis in colon cancer

Shikonin induces ROS-based mitochondria-mediated apoptosis in colon cancer

Tetramethylpyrazine inhibits proliferation of colon cancer cells in vitro

Advances in IKBKE as a potential target for cancer therapy

Contact Info

Product

Resources

About